Viimane versioon :
18/04/2024
Infostab
Ingredientide nimekiri
Nimekiri
Sobivus otsing
Y-liini sobivuse tabel
Viited
Uurimisrühmad
Valistab
Plakat
Sidemed
Sponsorid
Autor
Kasutusjuhend
Ajakiri
Viited 2296
Tüüp :
Labor
Uurimisrühmad :
Autor :
Pealkiri :
Témocilline (Negaban®) - Résumé des caractéristiques du produit
Publikatsioon :
Eumedica 2017
Tõendite tase :
Füüsikaline stabiilsus :
Keemiline püsivus :
Muud meetodid :
Kommentaarid :
Ingredientide nimekiri
Alemtuzumab
+
Temocilline
Amikacin sulfate
+
Temocilline
Atezolizumab
+
Temocilline
Belimumab
+
Temocilline
Bevacizumab
+
Temocilline
Blinatumomab
+
Temocilline
Brentuximab vedotin
+
Temocilline
Catumaxomab
+
Temocilline
Cetuximab
+
Temocilline
Daratumumab
+
Temocilline
Eculizumab
+
Temocilline
Gentamicin sulfate
+
Temocilline
Infliximab
+
Temocilline
Ipilimumab
+
Temocilline
Kanamycin sulfate
+
Temocilline
Natalizumab
+
Temocilline
Necitumumab
+
Temocilline
Netilmicin sulfate
+
Temocilline
Nivolumab
+
Temocilline
Obinutuzumab
+
Temocilline
Ofatumumab
+
Temocilline
Panitumumab
+
Temocilline
Pembrolizumab
+
Temocilline
Pertuzumab
+
Temocilline
Ramucirumab
+
Temocilline
Rituximab
+
Temocilline
Siltuximab
+
Temocilline
Sodium bicarbonate
+
Temocilline
Temocilline
125 mg/ml
25°C
24
125 mg/ml
25°C
24
125 mg/ml
25°C
24
125 mg/ml
25°C
24
+
+
+
+
Alemtuzumab
+
Amikacin sulfate
+
Atezolizumab
+
Belimumab
+
Bevacizumab
+
Blinatumomab
+
Brentuximab vedotin
+
Catumaxomab
+
Cetuximab
+
Daratumumab
+
Eculizumab
+
Gentamicin sulfate
+
Infliximab
+
Ipilimumab
+
Kanamycin sulfate
+
Natalizumab
+
Necitumumab
+
Netilmicin sulfate
+
Nivolumab
+
Obinutuzumab
+
Ofatumumab
+
Panitumumab
+
Pembrolizumab
+
Pertuzumab
+
Ramucirumab
+
Rituximab
+
Siltuximab
+
Sodium bicarbonate
+
Tobramycin sulfate
+
Trastuzumab
+
Trastuzumab emtansine
+
Vedolizumab
Tobramycin sulfate
+
Temocilline
Trastuzumab
+
Temocilline
Trastuzumab emtansine
+
Temocilline
Vedolizumab
+
Temocilline
Mentions Légales
